Behavioral therapy
CBT-I works for perinatal insomnia — and helps mood, too
At a glance
| Study type | Meta-analysis |
|---|---|
| Year | 2024 |
| Journal | Sleep and Biological Rhythms |
| Effect size | SMD = -0.62 (ISI) |
| Population | perinatal |
Background
A 2024 meta-analysis of 7 randomized controlled trials of cognitive-behavioral therapy for insomnia (CBT-I) in pregnant and postpartum participants. CBT-I reduced insomnia severity (ISI) with a medium-to-large effect (SMD = -0.62) and depressive symptoms (EPDS) with a small-to-moderate effect (SMD = -0.31).
What is CBT-I and why is it the first-line treatment for perinatal insomnia?
CBT-I is a structured, short-course (typically 4–8 sessions) program combining stimulus control, sleep restriction, cognitive restructuring, and sleep-hygiene education. The Feng 2024 meta-analysis pooled 7 RCTs in pregnant and postpartum cohorts and found a medium-to-large effect on insomnia severity (SMD = -0.62) — without fetal or infant exposure to medication. Obstetric and sleep-medicine guidelines recommend it first for that reason.
Does digital CBT-I work in pregnancy and postpartum?
Yes. The meta-analysis includes both digital and in-person delivery, and both produced significant improvement in insomnia severity. Digital delivery is acceptable when in-person access is limited — which is most of late pregnancy and the first 12 weeks postpartum.
Beyond sleep, does CBT-I improve mood symptoms in this population?
Yes — but the effect is smaller than the sleep effect. The pooled trials reported a SMD of -0.31 on the Edinburgh Postnatal Depression Scale (EPDS), which is a small-to-moderate effect. The probable mechanism is that sleep loss itself drives perinatal mood symptoms, so improving sleep relieves load on the mood system.
How big is SMD = -0.62, in plain English?
Standardized mean difference (SMD) of -0.62 means CBT-I moved insomnia severity about 0.62 standard deviations more than control. Conventionally that's 'medium-to-large' — meaningfully bigger than what sleep hygiene alone produces in trials, and close to what sedative medications produce, but without the side effects.
How does Solas use this finding?
Solas embeds CBT-I principles — stimulus control, fixed wake time, cognitive reframes for nighttime worry — into nightly recommendations, and points users with persistent insomnia (ISI ≥ 15) toward formal CBT-I programs rather than trying to substitute for therapy.
Source
Feng S, Dai B, Li H, Fu H, Zhou Y
(2024).
Efficacy of cognitive behavioral therapy for insomnia in the perinatal period: a meta-analysis of randomized controlled trials Sleep and Biological Rhythms.
DOI: 10.1007/s41105-023-00502-z
Read the original paper →
Solas does not own or distribute the underlying paper. Follow the link to the publisher for the full text. See our methodology.